Meagan Parrish
Lead Editor at Industry Dive
Lead Editor at PharmaVOICE
Senior editor for @industrydive, follower of the pharma world, proud mama, frequent flyer, occasional belly dancer.
Articles
-
2 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. Welcome to “Day in the Life,” a series examining what it’s like to walk in a pharma exec’s shoes. Today, we’re going behind the scenes with Maya Martinez-Davis, president of U.S. GSK, to learn how she balances frequent meetings and travel while the company goes to market with a string of new drugs.
-
3 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The market outlook from the perspective of many biotech CEOs is grim. When the investment environment stabilized following a post-pandemic crash, new headwinds began to pummel early-stage companies — and more pain is expected down the road, according to a recent survey by Incubate, an organization that represents venture capital firms.
-
4 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. Antibody-drug conjugates have become a “choose your own adventure” tool in pharma R&D. Due to their versatility, the therapies have proved themselves as a potent weapon against many oncology indications, AstraZeneca’s vice president and head of medical affairs for U.S. oncology told PharmaVoice last year. And the adventure more companies are choosing is solid tumors.
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
1 month ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. Diagnostics companies are having trouble escaping the shadow cast by Theranos, the blood testing biotech that failed in spectacular fashion. That challenge is already facing the new diagnostics startup Haemanthus — and it hasn’t even emerged from stealth.
-
1 month ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. AI-driven drug discovery has gotten much of the glory in pharma. Isomorphic Labs — which is leveraging an AI drug discovery platform based on Nobel Prize-winning AlphaFold software — pulled in the largest biotech investment haul this year to date with a $600 million fundraising round in March. And drug discovery is a prime focus for many of the highest valued AI companies working in pharma.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 295
- Tweets
- 110
- DMs Open
- No
Recently caught up with SIGA Technologies, one of the sole producers of a monkeypox treatment, to find out how they're preparing for the potential of an ongoing outbreak. Here's my report: https://t.co/jFudmaQuQh
There are a host of reasons pharma could get its M&A groove back in 2022. Here's a look at some of the leading market factors on the pharma M&A scene. https://t.co/KsO1vfnZlE
For one of my first PharmaVoice articles, I picked a really interesting company to write about. With a novel platform and innovative vaccines, @vaxxinity is worth having on your pharma radar. https://t.co/sUmGTUcFPp